{"url_path":"/sec/ctrvp/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-023136-index.html","accession_number":"0001493152-26-023136","cik":"0001583771","ticker":"HEPA","issuer_name":"Hepion Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-023136-index.html","primary_entity_key":"0001583771","primary_entity_name":"Hepion Pharmaceuticals, Inc."},"word_count":226,"has_tables":true,"body_markdown":"**ITEM\n6. EXHIBITS**\n\n \n\n10.1\n \n[Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on April 22, 2026)](https://www.sec.gov/Archives/edgar/data/1583771/000149315226018575/ex10-1.htm)\n\n10.2\n \n[Employment Agreement with Vincent LoPriore dated May 5, 2026](ex10-2.htm)\n\n10.3\n \n[Employment Agreement with Gary Stetz dated May 5, 2026](ex10-3.htm)\n\n31.1\n \n[Certification of Interim Chief Executive Officer and Interim Chief Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act.](ex31-1.htm)\n\n32.1\n \n[Certification of Interim Chief Executive Officer and Interim Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n\n101.INS\n \nInline\nXBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within\nthe Inline XBRL document.\n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema\n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase\n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase\n\n101.LAB\n \nInline\nXBRL Taxonomy Label Linkbase\n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase\n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL in Exhibit 101)\n\n \n\n22\n\n [Table of Contents](#toc_001)\n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\n** **\n**HEPION\nPHARMACEUTICALS, INC.** (Registrant)\n\n \n \n \n\nDate:\n5/14/2026\nBy:\n*/s/\nGARY STETZ*\n\n \n \nGary\nStetz\n\n* *\n* *\n*Interim\nChief Executive Officer*\n\n* *\n* *\n*(Principal\nExecutive Officer and Principal\nFinancial and Accounting Officer)*\n\n \n\n23"}